Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines

International Journal of Cancer

Volumn 73, Issue 3, 1997, Pages 362-366

  Bakker, Marleen ^a   Renes, Johan ^a   Groenhuijzen, Anneke ^a   Visser, Petra ^a   Timmer Bosscha, Hetty ^a   Müller, Michael ^a   Groen, Harry J M ^a   Smit, Egbert F ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 3' MORPHOLINODOXORUBICIN; GLYCOPROTEIN P;

ARTICLE; CELL COMPARTMENTALIZATION; CROSS RESISTANCE; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; DRUG TRANSPORT; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL; TUMOR RESISTANCE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MICROSCOPY, CONFOCAL; TUMOR CELLS, CULTURED;

EID: 0030716194     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971104)73:3<362::AID-IJC10>3.0.CO;2-F     Document Type: Article

References (20)

1. BAKKER, M., DROZ, J.P., HANAUSKE, A.R., VERWEIJ, J., VAN OOSTEROM, A.T., GROEN, H.J.M., PACCIARINI, M.A., DOMENIGONI, L., VAN WEISSENBRUCH, F., PIANEZZOLA, E. and DE VRIES, E.G.E., Broad phase II and pharmacokinetic study of methoxymorpholino doxorubicin (FCE 23762-MMRDX) in NSCLC, renal cancer, and other solid tumour patients. Brit. J. Cancer (1997) (In press).
2. BREDA, M., PIANEZZOLA, E. and STROLIN BENEDETTI, M., Determination of 3′-deamino3′-[2(S)-methoxy-4-morpholinyl]doxorubicin, a new morpholinylanthracycline, in plasma by performance liquid chromatography with fluorescence detection. J. Chromatogr., 578, 309-315 (1992).
3. CHAIRES, J.B., DATTAGUPTA, N. and CROTHERS, D.M., Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry, 21, 3933-3940 (1982).
4. COLE, S.P.C., BHARDWAJ, G., GERLACH, J.H., MACKIE, J.E., GRANT, C.E., ALMQUIST, K.C., STEWART, A.J., KURZ, E.U., DUNCAN, A.M.V. and DEELEY, R.G., Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-1654 (1992).
5. COLEY, H.M., AMOS, W.B., TWENTYMAN, P.R. and WORKMAN, P., Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrua resistant cell lines. Brit. J. Cancer, 67, 1316-1323 (1993).
6. COLEY, H.M., TWENTYMAN, P.R. and WORKMAN, P., Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem. Pharmacol., 38, 4467-4475 (1989a).
7. COLEY, H.M., TWENTYMAN, P.R. and WORKMAN, P., Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother. Pharmacol., 24, 284-290 (1989b).
8. DE JONG, S., ZIJLSTRA, J.G., MULDER, N.H. and DE VRIES, E.G.E., Lack of cross-resistance to fostriecin in a human small cell carcinoma cell line with topoisomerase II related drug-resistance. Cancer Chemother. Pharmacol., 28, 461-464 (1991).
9. 4-Adr is MRP mediated. Proc. Amer. Ass. Cancer Res., 37, 306 (1996).
10. FLENS, M.J., IZOUIRDO, M.A., SCHEFFER, G.L., FRITZ, J.M., MEIJER, C.J.L.M., SCHEPER, R.J. and ZAMAN, J.R., Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54, 4557-4563 (1994).
11. GRANDI, M., PEZZONI, G., BALLINARI, D., CAPOLONGO, L., SUARATO, A., BARGIOTTI, A., FAIARDI, D. and SPREAFICO, F., Novel anthracycline analogs. Cancer Treat. Rev., 17, 133-138 (1990).
12. JOHNSTON, J.B. and GLAZER, R.I., Cellular pharmacology of 3′-(4morpholinyl) and 3′-(4-methoxy-1-piperidinyl) derivatives of 3′-deuminodaunorubicin in human colon carcinoma cells in vitro. Cancer Res., 43, 1606-1610 (1983a).
13. JOHNSTON, J.B. and GLAZER, R.I., Pharmacological studies of 3′-(4morpholinyl)-3′-deaminodaunorubicin in human colon carcinoma cells in vitro. Cancer Res., 43, 1044-1048 (1983b).
14. 4 and structurally related conjugates. J. biol. Chew., 269, 27808-27810 (1994).
15. ROGAN, A.M., HAMILTON, T.C., YOUNG, R.C., KLECKER, R.W. and OZOLS, R.F., Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science, 224, 994-996 (1984).
16. ScHUURHUIS, G.J., BROXTERMAN, H.J., CERVANTES, A., VAN HEININGEN, T.H.M., DE LANGE, J.H.M., BAAK, J.P.A., PINEDO, H.M. and LANKELMA, J., Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J. nat. Cancer Inst., 81, 1887-1892 (1989).
17. SCHUURHUIS, G.J., BROXTERMAN, H.J., DE LANGE, J.H.M., PINEDO, H.M., VAN HEIJNINGEN, H.J.M., KUIPER, C.M., SCHEFFER, G.L., SCHEPER, R.J., VAN KALKEN, C.K., BAAK, J.P.A. and LANKELMA, J., Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Brit. J. Cancer, 64, 857-861 (1991).
18. WASSERMANN, K., MARKOVITS, J., JAXEL, C., CAPRANICO, G., KOHN, K.W. and POMMIER, Y., Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol., 38, 38-45 (1990).
19. ZAMAN, G.J.R., FLENS, M.J., VAN LEUSDEN, M.R., DE HAAS, M., MULDER, H.S., LANKELMA, J., PINEDO, H.M., SCHEPER, R.J., BAAS, F., BROXTERMAN, H.J. and BORST, P., The human multidrug resistance-associated protein MRP is a plasma membrane efflux pump. Proc. nat. Acad. Sci. (Wash.), 91, 8822-8826 (1994).
20. ZIJLSTRA, J.G., DE VRIES, E.G.E. and MULDER, N.H., Multifactorial drug resistance in an adriamycin-resistam human small cell lung cancer cell line. Cancer Res., 47, 1780-1784 (1987).